Chemoprevention for Atypical Ductal Hyperplasia
For postmenopausal women with atypical ductal hyperplasia (ADH), offer anastrozole 1 mg daily for 5 years as first-line chemoprevention, with exemestane 25 mg daily as an alternative; for premenopausal women, offer tamoxifen 20 mg daily for 5 years. 1
Postmenopausal Women: Aromatase Inhibitors Preferred
The 2019 ASCO guidelines provide strong, evidence-based recommendations specifically naming ADH as a high-priority indication for chemoprevention. Anastrozole should be discussed as an alternative to tamoxifen, raloxifene, or exemestane to reduce invasive breast cancer risk in postmenopausal women with atypical ductal hyperplasia. 1
Agent Selection Algorithm:
First-line options for postmenopausal women:
- Anastrozole 1 mg/day orally for 5 years (strong recommendation, high-quality evidence) 1
- Exemestane 25 mg/day orally for 5 years (moderate recommendation, moderate-quality evidence) 1
- Raloxifene 60 mg/day for 5 years (if aromatase inhibitors contraindicated)
- Tamoxifen 20 mg/day for 5 years (if aromatase inhibitors contraindicated)
Critical Pre-Treatment Evaluation for Aromatase Inhibitors:
Before initiating anastrozole or exemestane, you must:
- Evaluate baseline fracture risk and measure bone mineral density (DEXA scan) 1
- Use anastrozole with caution if moderate bone loss present; consider bisphosphonates or RANKL inhibitors concurrently
- Severe osteoporosis (T-score < -4 or >2 vertebral fractures) is a relative contraindication 1
- In women with severe bone loss, choose tamoxifen or raloxifene instead, as these do not reduce bone density
All patients on aromatase inhibitors should:
- Exercise regularly
- Take adequate calcium and vitamin D supplementation
- Be counseled about joint stiffness, arthralgias, vasomotor symptoms, hypertension, dry eyes, and vaginal dryness 1
Premenopausal Women: Tamoxifen Only
Do not prescribe anastrozole, exemestane, or raloxifene for breast cancer risk reduction in premenopausal women. 1 For premenopausal women with ADH, tamoxifen 20 mg daily for 5 years is the appropriate option.
Tamoxifen Contraindications:
Do not use tamoxifen in women with:
- History of deep vein thrombosis or pulmonary embolus
- History of stroke or transient ischemic attack
- Anticipated prolonged immobilization 1
Quantifying the Benefit
Women with ADH have substantial breast cancer risk. Observational data shows:
- 10-year breast cancer risk with ADH is approximately 17.3% without chemoprevention 2
- Chemoprevention reduces 10-year risk to 7.5% (p < 0.001) 2
- This represents a clinically meaningful absolute risk reduction of approximately 14%
Recent real-world data demonstrates that 19% of women with atypical hyperplasia initiate chemoprevention, with low-dose tamoxifen (5 mg daily) emerging as an option with potentially fewer adverse events than standard dosing 3. However, the ASCO guidelines are based on standard dosing regimens.
Risk Assessment Threshold
Women with ADH automatically qualify for chemoprevention based on the diagnosis alone. However, the ASCO guidelines specify that women most likely to benefit are those with:
- A diagnosis of atypical ductal or lobular hyperplasia (this is sufficient by itself) 1
- OR 5-year risk (NCI BCRAT) ≥ 3%
- OR 10-year risk (IBIS/Tyrer-Cuzick) ≥ 5%
- OR relative risk ≥4× population risk (age 40-44) or ≥2× population risk (age 45-69)
Common Pitfalls to Avoid
Do not withhold chemoprevention discussion from all ADH patients - The diagnosis itself warrants comprehensive risk assessment and counseling about risk-reducing strategies 4, 5
Do not prescribe aromatase inhibitors to premenopausal women - This is explicitly contraindicated 1
Do not start aromatase inhibitors without baseline bone density assessment - This creates liability for osteoporotic fractures 1
Do not assume all ADH requires surgical excision - Recent evidence suggests selected low-risk ADH cases meeting strict criteria can be actively monitored 6, though this remains controversial and requires multidisciplinary consensus
Ensure strong physician recommendation - System-level data shows that 98% of patients should receive a recommendation for preventive therapy, and uptake is significantly higher when offered at time of diagnosis 7
Strength of Evidence
The ASCO recommendations carry strong evidence-based recommendations with high-quality evidence from multiple randomized controlled trials with low risk of bias 1. The evidence specifically addresses mortality and morbidity outcomes by reducing invasive ER-positive breast cancer incidence, which directly impacts long-term survival and quality of life.